MedImmune, Inc. v. Genentech, Inc.

MedImmune, Inc. v. Genentech, Inc.

Argued October 4, 2006
Decided January 9, 2007
Full case name MedImmune, Inc. v. Genentech, Inc.
Docket nos. 05-608
Citations

549 U.S. 118 (more)

Holding
Contrary to respondents’ assertion that only a freestanding patent-invalidity claim is at issue, the record establishes that petitioner has raised and preserved the contract claim that, because of patent invalidity, unenforceability, and noninfringement, no royalties are owing. 427 F. 3d 958, reversed and remanded.
Court membership
Chief Justice
John G. Roberts
Case opinions
Majority Scalia, joined by Roberts, Stevens, Kennedy, Souter, Ginsburg, Breyer, Alito
Dissent Thomas

MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007) was a decision by the Supreme Court of the United States involving patent law. It arose from a lawsuit filed by MedImmune which challenged one of the Cabilly patents issued to Genentech. One of the central issues was whether a licensee retained the right to challenge a licensed patent, or whether this right was forfeited upon signing of the license agreement. The case related indirectly to past debate over whether the US should change to a first to file patent system - in 2011, President Obama signed the Leahy-Smith America Invents Act, which shifted the United States to a first to file patent system.

The origin of the dispute was a lengthy interference proceeding between Genentech and Celltech which led to the issuance of a new patent in 2001, 18 years after the original filing. This effectively granted Genentech a patent term of 29 years.[1] MedImmune was a licensee of the later Cabilly patent, but argued that the term had been improperly extended and that it need not continue to pay royalties past the original expiry date in March 2006. The case was decided in favor of MedImmune, and the United States Patent and Trademark Office (USPTO) declared the patent invalid. Genentech appealed the USPTO the ruling and the patent remained valid and enforceable until the appeal was concluded. Genentech prevailed during the reexamination of Cabilly II(2) by the USPTO (1). GlaxoSmithKline and Human Genome Sciences both are challenging the patent under antitrust law (1). This is based on the settlement between Genentech and Celltech and their dispute over the original Cabilly patent 4,816,567 and the Celltech's patent 4,816,397. Both of which issued on March 28, 1989 (2),(3). Cabilly II is patent 6331415(4) which issued December 18, 2001.

Holding

The Court held[2] that:

1 licensee adequately raised and preserved its contract claim;
2 licensee was not required to terminate or breach license agreement prior to seeking declaratory judgment of patent invalidity, abrogating Gen–Probe Inc. v. Vysis, Inc., 359 F.3d 1376; and
3 Supreme Court would not address whether action was subject to dismissal on discretionary grounds.

Reversed and remanded.

Justice Thomas filed a dissenting opinion.

References

  1. ↑ Carter, Eugenia G. "IP Licensing and the Supreme Court’s Medimmune v. Genentech Decision" (PDF). Wisconsin Intellectual Property Law Association. Retrieved March 22, 2007.
  2. ↑ "MEDIMMUNE, INC., Petitioner, v. GENENTECH, INC., et al. No. 05-608." (PDF). WestLaw.

Further reading

External links

This article is issued from Wikipedia - version of the Friday, March 25, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.